PS
DNTH icon

Principal Securities’s Dianthus Therapeutics DNTH Stock Holding History

Principal Securities’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11
Closed -$433 – 1893
2025
Q3 		$433 Hold
11
– – ﹤0.01% 3559
2025
Q2 		$205 Buy
+11
New +$206 ﹤0.01% 3598

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Principal Securities's DNTH Position: Q4 2025 in Review

Principal Securities sold out of Dianthus Therapeutics (DNTH) in Q4 2025, closing a stake of 11 shares — an estimated $433 sold.

Principal Securities first reported a position in DNTH in Q2 2025 and held it in 2 quarters. The position peaked at $433 in Q3 2025. 165 funds tracked by Wall St. Rank hold DNTH as of Q4 2025.

  • Principal Securities reported no remaining Dianthus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 11 Dianthus Therapeutics shares in Q4 2025, an estimated $433.
  • Principal Securities first reported a position in Dianthus Therapeutics in Q2 2025 and held it in 2 quarters.
  • Principal Securities's Dianthus Therapeutics position peaked at $433 in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.